CLINICAL_TRIALS
research
· 2026-04-17
Clinical Trial Update: A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) [Phase 1]
Summary
The SHAKTI-1 Phase 1 trial evaluating AUR107 in patients with relapsed malignant solid neoplasms is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Aurigene Discovery Technologies Limited | Conditions: Relapsed Malignant Solid Neoplasm | Phase 1 | Status: RECRUITING